ScholarLens Back to search
2015•Journal for ImmunoTherapy of CancerOpen access

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

Robert Chen, Phillippe Armand, Michelle A. Fanale, Vincent Ribrag, Pier Luigi Zinzani, Alejandro Daniel Ricart, Seth Thompson, Arun Balakumaran, Daniel L. Molin, Margaret Ann Shipp, Craig H. Moskowitz

Open full text 1 citations

Abstract

Meeting abstracts The prognosis is poor for patients with cHL who relapse after autologous stem-cell transplant (auto-SCT) or progress after brentuximab vedotin (BV) therapy. cHL frequently harbors genetic amplification at 9p24.1, which leads to overexpression of PD-L1 and PD-L2 on the tumor cell

Open-access reader

About this research paper

What this paper is about

Meeting abstracts The prognosis is poor for patients with cHL who relapse after autologous stem-cell transplant (auto-SCT) or progress after brentuximab vedotin (BV) therapy. cHL frequently harbors genetic amplification at 9p24.1, which leads to overexpression of PD-L1 and PD-L2 on the tumor cell

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Meeting abstracts The prognosis is poor for patients with cHL who relapse after autologous stem-cell transplant (auto-SCT) or progress after brentuximab vedotin (BV) therapy. cHL frequently harbors genetic amplification at 9p24.1, which leads to overexpression of PD-L1 and PD-L2 on the tumor cell

Key concepts: Brentuximab vedotin, Classical Hodgkin lymphoma, Pembrolizumab, Medicine, Oncology, Refractory (planetary science), Internal medicine, Cancer research

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 — Research Paper | ScholarLens